Furan in Food Summary and Charge to the FAC and SCNT Terry C. Troxell, Ph.D. Director Office of Plant and Dairy Foods FDA Center for Food Safety and Applied.

Slides:



Advertisements
Similar presentations
Evaluation of a potential mutagenic MOA based on analysis of the weight of evidence and using the modified Hill criteria Martha M. Moore, Ph.D. Director,
Advertisements

Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
Risk Assessment.
Carcinogen Classification Criteria Patricia Richter Ph.D., DABT Tobacco Products Scientific Advisory Committee June 8, 2010.
Guidelines for Carcinogen Risk Assessment and Supplemental Guidance for Assessing Cancer Risks from Early-Life Exposures March 29, 2005 Hugh A. Barton,
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
William H. Farland, Ph.D. Acting Deputy Assistant Administrator for Science Office of Research and Development U.S. ENVIRONMENTAL PROTECTION AGENCY Biomarkers:
Toxicological Assessment Heinz Hofer ARC Seibersdorf research GmbH Department of Toxicology.
Major Components of FDA’s Action Plan for Acrylamide Richard Canady, PhD DABT US Food and Drug Administration Center for Food Safety and Applied Nutrition.
Risk Assessment.
What Do Toxicologists Do?
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
Considerations for Food Contact Materials for Foods for Infants Susceptible Populations Food Advisory Committee Meeting Tuesday, December 16 th, 2014 April.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Food Safety Assessment Kevin Greenlees, PhD, DABT Kathleen Jones, PhD.
Ohio Nano-Summit March 3, 2005 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D. Associate.
June 16-19, USEPA Cancer Guidelines: Mode of Carcinogenic Action 1 ICABR – Impacts of the Bioeconomy on Agricultural Sustainability, the Environment.
Overview of Acetaminophen Label Warnings William E. Gilbertson, PharmD. Division OTC Drug Products 1.
ILSI Risk Science Institute Acrylamide Toxicity: Research to Address Key Data Gaps Presented by Dr. Stephen S. Olin ILSI Risk Science Institute.
Risk assessment: Bt corn MON810 Risk assessment: identifying and evaluating possible dangers predicting the chances the danger will occur assessing the.
Toxicology Component of FDA’s Action Plan for Acrylamide Richard Canady, PhD DABT US Food and Drug Administration Center for Food Safety and Applied Nutrition.
Food Advisory Committee Meeting December 16 and 17, 2014 Questions to the Committee Suzanne C. Fitzpatrick, PhD, DABT Senior Advisory for Toxicology Center.
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
Committee on Carcinogenicity (COC) Approach to Risk Assessment of Genotoxic Carcinogens David H. Phillips* COC Chairman Descriptive vs. Quantitative.
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
28/05/12 Questions (Rispondete alle domande che seguono usando il colore rosso per il testo) Tossicologia - Rubbiani Maristella.
Dr. Manfred Wentz Director, Hohenstein Institutes (USA) Head, Oeko-Tex Certification Body (USA) AAFA – Environmental Committee Meeting November 10, 2008.
TRAINING FOR THE HEALTH SECTOR
Examining Bioaccumulation & Biomagnification: Implications for Ecosystems and Human Health.
1 FAO/WHO Seminar on Acrylamide in Food, Arusha, 16 March 2003 EU Commission Perspective on Acrylamide in Food Dr Martin Slayne European Commission Directorate.
Brownfields Health Risks & Remediation Diogo Cadima Topic ‘A’ Term Project CET 413.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Exploratory IND Studies
Chapter 15 Environmental Health, Pollution and Toxicology.
Chapter 15 Environmental Health, Pollution and Toxicology.
U.S. Action Plan for Acrylamide Activities and Progress Terry Troxell, Ph.D.and Lauren Posnick, Sc.D., U.S. FDA March 16, 2003 FAO/WHO Seminar on Acrylamide.
Forging Partnerships on Emerging Contaminants November 2, 2005 John Vandenberg Associate Director for Health National Center for Environmental Assessment.
Copyright © 2002 University of Maryland School of Nursing. All rights reserved. Comparison of Pharmacology and Toxicology This material was developed at.
Risk Assessments: Models for Estimating the Risk of Transmitting TSE by Human Tissue Intended for Transplantation Rolf E. Taffs, Ph.D. Center for Biologics.
Implications of the Current State of Scientific Knowledge David W K Acheson, M.D. Center for Food Safety and Applied Nutrition U.S. Food and Drug Administration.
Major Components of FDA’s Action Plan for Acrylamide Richard Canady, PhD DABT US Food and Drug Administration Center for Food Safety and Applied Nutrition.
Biomarkers Biomarkers - markers in biological systems with a sufficently long half-life which allow location where in the biological system change occur.
June 8, 2004Seafood: Assessing the Benefits and Risks1 of 17 Assessing and Managing the Risks Associated With Eating Seafood Don Schaffner, Ph.D. Professor.
CALIFORNIA proposed SAFER CONSUMER PRODUCT REGULATIONS Marjorie MartzEmerson October 24, 2012.
MAIN TOXICITY TESTING. TESTING STRATEGIES A number of different types of data are used in order to establish the safety of chemical substances for use.
Food Advisory Committee Meeting Risk Ranking and Risk Prioritization Chemical Contaminants September 29-30, 2014 Nega Beru, Ph.D. Director, Office of Food.
Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.
Pollution and Human Health
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.
Background on Furan in Foods Nega Beru, Ph.D. Director, Division of Plant Product Safety Office of Plant and Dairy Foods Center for Food and Applied Nutrition.
Risk Assessment.
1 Operation of the Prescription Drug User Fee Program Janet Woodcock, M.D. Deputy Commissioner for Operations November 14, 2005.
UPDATE: Nonclinical Reproductive Toxicity Information in Assessing Human Risk Joseph J. DeGeorge Ph.D. Associate Director for Pharmacology and Toxicology.
Part 1d: Exposure Assessment and Modeling Thomas Robins, MD, MPH.
DoD Comments to NRC Committee on Improvements to EPA Risk Analysis Yvonne P. Walker, MS, MSE, CIH Director, Environmental Programs Navy Environmental Health.
Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,
Substance Structure, production process and indented use Is there adequate published safety data and exposure data for this substance to meet current GRAS.
Perspective on the current state-of-knowledge of mode of action as it relates to the dose response assessment of cancer and noncancer toxicity Jennifer.
Office of Research and Development National Center for Environmental Assessment Human Health Risk Assessment and Information for SRP July 28, 2009 Reeder.
1. Consumers, Health, Agriculture and Food Executive Agency Risk assessment with regard to food and feed safety Risk analysis Why risk assessment in the.
James G. Farrelly, Ph.D. Pharmacology Team Leader Division of Antiviral Drug Products Center for Drug Evaluation and Research Food and Drug Administration.
Summation of Toxicity Data in Vitic Andrew Thresher
Lecture 4: Risk Analysis
Drug Discovery &Development
THE DOSE MAKES THE POISON
Regulatory Sciences and Government Affairs
Environmental Health, Pollution and Toxicology
VICH GL 54, Studies to evaluate the safety of residues of veterinary drugs in human food: General approach to establish an Acute Reference Dose (ARfD)
Presentation transcript:

Furan in Food Summary and Charge to the FAC and SCNT Terry C. Troxell, Ph.D. Director Office of Plant and Dairy Foods FDA Center for Food Safety and Applied Nutrition June 8, 2004

FDA actions on furan in food Development of quantitative method Development of quantitative method –Available on CFSAN website –Undergoing round robin testing Exploratory survey Exploratory survey –More than 150 infant and adult foods tested –Testing of more foods underway

FDA actions on furan in food Preliminary exposure assessment Preliminary exposure assessment FR request for data and information FR request for data and information International interactions International interactions –Already yielding advances in understanding formation

Some future actions on furan in food Evaluation of received dataEvaluation of received data Review of NTP study by Cancer Assessment Committee (CAC)Review of NTP study by Cancer Assessment Committee (CAC) Development of Action PlanDevelopment of Action Plan

Data Needs: Occurrence and Exposure Particular foods in which furan occurs Particular foods in which furan occurs Levels of furan in these foods Levels of furan in these foods Formation and occurrence in home- prepared foods Formation and occurrence in home- prepared foods Environmental sources of exposure to furan for the typical consumer Environmental sources of exposure to furan for the typical consumer

Data Needs: Mechanisms of Formation Possible mechanisms of furan formation Possible mechanisms of furan formation Variables that enhance or mitigate furan formation Variables that enhance or mitigate furan formation The stability or dissipation of furan in foods The stability or dissipation of furan in foods The effect of post-production practices on furan levels in foods The effect of post-production practices on furan levels in foods

Data Needs: Toxicology of Furan Mechanism(s) of furan toxicity, mutagenicity, and carcinogenesis Mechanism(s) of furan toxicity, mutagenicity, and carcinogenesis The reproductive and developmental toxicology of furan The reproductive and developmental toxicology of furan The metabolism of furan in vivo including characterization of reactive furan metabolites The metabolism of furan in vivo including characterization of reactive furan metabolites

Data Needs: Toxicology of Furan The diversity of furan pharmacokinetics in humans or the alteration of furan metabolism as a result of dietary, medical, or environmental interactions The diversity of furan pharmacokinetics in humans or the alteration of furan metabolism as a result of dietary, medical, or environmental interactions Data on whether sub-cytotoxic furan doses produce any adverse effects, such as a change in enzyme activities or ATP levels Data on whether sub-cytotoxic furan doses produce any adverse effects, such as a change in enzyme activities or ATP levels

Data Needs: Toxicology of Furan The effects of furan doses lower than those used in the NTP study The effects of furan doses lower than those used in the NTP study –To establish a dose-response curve for various toxicological endpoints –To determine whether furan toxicity, including carcinogenesis, is a threshold dependent event –To determine whether carcinogenic activity is secondary to hepatotoxic effects

Data Needs: Toxicology of Furan The mutagenicity of furan in the TA100 strain in the Ames test The mutagenicity of furan in the TA100 strain in the Ames test The behavior of furan in other in vivo assays for mutagenicity or toxicity The behavior of furan in other in vivo assays for mutagenicity or toxicity

Charge The Food Advisory Committee and Contaminants and Natural Toxicants Subcommittee are being asked to provide input on data that would be helpful for further evaluation of potential risks posed by the presence of furan in food.

Question Taking into consideration the data needs already identified in the Federal Register notice requesting data on furan, and the presentations at this meeting, are there any additional data that are needed to fully assess the risk of furan in food?

Thank you for your participation in the FAC/SCNT meeting on furan in food.